How has been the historical performance of Biogen Pharma?

Answer:The historical performance of Biogen Pharma shows a fluctuating trend in its financial metrics over the years, with significant challenges in generating consistent revenue.

Breakdown:
Biogen Pharma's net sales have remained stagnant at zero from March 2023 to March 2025, with a slight increase to 2.47 Cr in March 2022 and 1.62 Cr in March 2021. Other operating income peaked at 2.38 Cr in March 2024 but dropped to 0.84 Cr in March 2025. Total operating income followed a similar pattern, reaching 2.38 Cr in March 2024 before declining to 0.84 Cr in March 2025. The company faced considerable expenditure, with total expenditure excluding depreciation rising to 1.13 Cr in March 2025 from 0.45 Cr in March 2024. This resulted in an operating profit (PBDIT) of -0.29 Cr in March 2025, a decline from 1.93 Cr in March 2024. Profit before tax mirrored this trend, showing a loss of -0.29 Cr in March 2025 compared to a profit of 1.93 Cr in March 2024. The company's reserves have been negative, with -9.03 Cr in March 2025, indicating ongoing financial distress. Total assets increased to 92.02 Cr in March 2025 from 56.82 Cr in March 2024, while total liabilities also rose to 92.02 Cr in March 2025. Cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive cash flow of 1.00 Cr in March 2024. Overall, Biogen Pharma's financial performance reflects significant volatility and challenges in achieving profitability and sustainable growth.